BioSpace News Archive

TFF Pharmaceuticals, Inc. today announced that it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial (CT.gov identifier NCT05168644) of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases.

Lipocine Inc. today announced the peer-reviewed publication of positive Phase 3 clinical data from the Dosing Validation (“DV”) study which evaluated the fixed-dose oral testosterone undecanoate, TLANDO, for the treatment of hypogonadism.

InnovHeart and Grand Pharmaceutical Group Enter Into an Exclusive License Agreement to Develop and Commercialize the Saturn TMVR Device in Greater China.

Ostentus Therapeutics, Inc. , has entered into a Sponsored Research Agreement with City of Hope, a world-renowned cancer treatment and research organization and a National Cancer Institute-designated Comprehensive Cancer Center, to conduct preclinical research on OST compounds, which could be used as future therapies for leukemia and other cancers.

Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI).

Kula Bio , a leader in sustainable nitrogen solutions, announced today it has closed a $50 million Series A.